期刊文献+

口服替吉奥联合顺铂治疗晚期三阴性乳腺癌临床观察 被引量:3

下载PDF
导出
摘要 目的:观察口服替吉奥联合顺铂治疗晚期三阴性乳腺癌的疗效及不良反应。方法:采用口服替吉奥联合顺铂治疗,口服替吉奥按80mg/(m2·日),分2次餐后半小时服用,d1-14,顺铂30mg/m2,d1-3,每3周为1个化疗周期,所有病例均接受至少2个周期的化疗。结果:36例均为晚期,接受过含蒽环及紫杉类术后辅助化疗方案,均可行疗效评价及不良反应评价。其中完全缓解2例,部分缓解13例,总有效率41.67%。主要不良反应为骨髓毒性及手足综合征,均相对较轻,无静脉炎发生。结论:口服替吉奥联合顺铂治疗晚期三阴性乳腺癌有较好的疗效,不良反应小。
作者 孙义长
出处 《中国社区医师(医学专业)》 2012年第22期141-142,共2页
  • 相关文献

参考文献2

二级参考文献12

  • 1Mansour E G, Gray R, Shatila A H, et al. Survival advantage of adjuvant chemotherapy in high-risk node-negative breast cancer: ten-year analysis -- an intergroup study[J]. J Clin Oncol, 1998, 16(11) : 3486-3492.
  • 2Goldhirsch A, Glick J H, Gelber R D, et aL Meeting highlights: In- ternational consensus panel on the treatment of primary breast cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer [J]. J Clin Oneol, 2001, 19(18): 3817 -3827.
  • 3Hara F, Kiyoto S, Takahashi M, et al. Efficacy and safety of S-1 in patients with metastatic breast cancer: retrospective review in a single institution[J]. Oncology, 2010, 79 (3/4): 273-277.
  • 4Shien T, Shimizu C, Akashi-Tanaka S, et al. Clinical efficacy of S-1 in pretreated metastatic breast cancer patients [ J ]. [ My paper ] Jpn J Clin Oncol, 2008, 38 (3) : 172 - 175.
  • 5Baur M, van-Oosterom A T, Dieras V, et al. A phase Ⅱ trial of docetaxel (Taxotere) as second-line chemotherapy in patients with metastatic breast cancer[J]. J Cancer Res Clin Oncol, 2008, 134(2) : 125 -135.
  • 6Saek T, Takashima S, Sane M, et al. A phase Ⅱ study of S-1 in pa- tients with metastatic breast cancer -- a Japanese trial by the S-1 Coop- erative Study Group, Breast Cancer Working Group [ J ]. Breast Canc- er, 2004, 11(2) : 194 -202.
  • 7Sato Y, Takayama T, Sagawa T, et al. Phase Ⅱ study of S-1, do- cetaxel and cisplatin combination chemotherapy in patients with unre- sectable metastatic gastric cancer [ J ]. Cancer Chemother Pharmacol, 2010, 66(4): 721 -728.
  • 8Suto A, Kubota T, Fukushima M, et al. Antitumor effect of combina- tion of S-1 and docetaxel on the human breast cancer xenograft trans- planted into SCID mice[J]. Oncol Rep, 2006, 15(6) : 1517 -1522.
  • 9Taira N, Aogi K, Ohsumi S, et al. S-1 (TS-1) maintained complete response for approximately 10 years in a case of metastatic breast cancer [J].Breast Cancer, 2006, 13(2): 220-224.
  • 10Vallbohmer D, Yang D Y, Kuramochi H, et al. DPD is a molecular determinant of capecitabine efficacy in colorectal cancer [ J ]. Int J Oncol, 2007, 31 (2): 413-418.

共引文献20

同被引文献20

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部